{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:53Z","timestamp":1791896513329,"version":"4.3.4"},"reference-count":25,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca K.K."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,7,18]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We assessed the safety, tolerability, pharmacokinetics, preliminary antitumour activity and pharmacodynamics of danvatirsen, an antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3), monotherapy and danvatirsen plus durvalumab, an antiprogrammed cell death ligand 1 monoclonal antibody, in patients with advanced solid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Phase 1, open-label study with two cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Two centres in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Japanese individuals aged \u226520 years, with histologically confirmed solid malignancies, except for hepatocellular carcinoma, refractory to standard therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>In cohort 1, patients received danvatirsen monotherapy; in cohort 2, patients received danvatirsen plus durvalumab combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was safety and tolerability based on adverse events (AEs). Secondary endpoints were pharmacokinetics, immunogenicity, antitumour activity and pharmacodynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven patients were assigned to treatment and included in the analysis. Danvatirsen dose reductions were only required in cohort 2 for hepatic function abnormal (alanine aminotransferase (ALT)\/ aspartate aminotransferase (AST)\/gamma-glutamyl transferase (\u03b3GT) increased), neutrophil count decreased and platelet count decreased. One patient experienced grade 3 ALT\/AST increased and new appearance of eosinophilia as a dose-limiting toxicity. AEs were reported in 90.9% (10\/11) patients. Commonly reported AEs causally related to the danvatirsen were platelet count decreased (60% (3\/5)) and ALT\/AST\/\u03b3GT increased (50% (3\/6)) in cohorts 1 and 2, respectively; none was causally related to durvalumab. One serious AE occurred in cohort 1 (pancreatitis; unrelated to study treatment). One case of ALT\/AST\/\u03b3GT increased occurred in cohort 2, leading to discontinuation. No AEs led to death. Danvatirsen did not accumulate in plasma after multiple dosing. In cohort 2, three patients had disease control at 12 weeks and one had unconfirmed partial response. STAT3 expression tended to decrease regardless of monotherapy or combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Danvatirsen was well tolerated by Japanese patients with advanced solid tumours as monotherapy and combined with durvalumab. No new safety signals arose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03394144\">NCT03394144<\/jats:ext-link>\n                      ; ClinicalTrials.gov.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-055718","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:03:35Z","timestamp":1666346615000},"page":"e055718","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03394144","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02499328","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-3757","authenticated-orcid":false,"given":"Tomohiro","family":"Nishina","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6629-6380","authenticated-orcid":false,"given":"Tomoko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-2564","authenticated-orcid":false,"given":"Naoto","family":"Yoshizuka","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-8054","authenticated-orcid":false,"given":"Ko","family":"Sugibayashi","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-9966","authenticated-orcid":false,"given":"Kosho","family":"Murayama","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-953X","authenticated-orcid":false,"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2025121400264836000_12.10.e055718.1","doi-asserted-by":"publisher","DOI":"10.1038\/srep17663"},{"key":"2025121400264836000_12.10.e055718.2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1995"},{"key":"2025121400264836000_12.10.e055718.3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","article-title":"Novel activators and small-molecule inhibitors of STAT3 in cancer","volume":"49","author":"Yang","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025121400264836000_12.10.e055718.4","doi-asserted-by":"crossref","DOI":"10.1038\/srep21731","article-title":"Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma","volume":"6","author":"Cao","year":"2016","journal-title":"Sci Rep"},{"key":"2025121400264836000_12.10.e055718.5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00748","article-title":"Inhibition of the STAT3 signaling pathway contributes to the anti-melanoma activities of shikonin","volume":"11","author":"Cao","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025121400264836000_12.10.e055718.6","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-90"},{"key":"2025121400264836000_12.10.e055718.7","doi-asserted-by":"publisher","DOI":"10.1021\/jo902560f"},{"key":"2025121400264836000_12.10.e055718.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1066"},{"key":"2025121400264836000_12.10.e055718.9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5272"},{"key":"2025121400264836000_12.10.e055718.10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0436-5"},{"key":"2025121400264836000_12.10.e055718.11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10928-019-09619-6","article-title":"Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch","volume":"46","author":"Xu","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025121400264836000_12.10.e055718.12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"2025121400264836000_12.10.e055718.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2025121400264836000_12.10.e055718.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2025121400264836000_12.10.e055718.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158"},{"key":"2025121400264836000_12.10.e055718.16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/cas.14003","article-title":"Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors","volume":"110","author":"Fujiwara","year":"2019","journal-title":"Cancer Sci"},{"key":"2025121400264836000_12.10.e055718.17","doi-asserted-by":"crossref","first-page":"viii372","DOI":"10.1093\/annonc\/mdy287","article-title":"A phase Ib\/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent\/metastatic head and neck squamous cell carcinoma (RM-HNSCC): updated results","volume":"29","author":"Cohen","year":"2018","journal-title":"Ann Oncol"},{"key":"2025121400264836000_12.10.e055718.18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025121400264836000_12.10.e055718.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025121400264836000_12.10.e055718.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2025121400264836000_12.10.e055718.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.04.017"},{"key":"2025121400264836000_12.10.e055718.22","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314551840"},{"key":"2025121400264836000_12.10.e055718.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.01.013"},{"key":"2025121400264836000_12.10.e055718.24","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712461047"},{"key":"2025121400264836000_12.10.e055718.25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1638"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-055718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:26:56Z","timestamp":1765700816000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-055718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2021-055718"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-055718","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}